2025
  • Metan G, Çiftçioğlu A, Saba R, Kılıç AU, Özdemir K, Çağ Y, Ünal DK, Aksoy F, Berk H, Mert G, Tunçcan ÖG, Tombak A, Balkan İİ, Çavuş SA, Kandemir B, Mutlu B, İnkaya AÇ, Kaynar L, Atay MH, Dursun FE, Saydam G, Ünsal Y, Sarı SF, Akan H; Study group. Antifungal Prophylaxis and Treatment of Breakthrough Invasive Fungal Diseases in High-Risk Hematology Patients.A Prospective Observational Multicenter Study. Indian J Hematol Blood Transfus 2025 Jan;41(1):75-88. doi: 10.1007/s12288-024-01790-2.

            https://pubmed.ncbi.nlm.nih.gov/39917507/

  • Kara E, Metan G, Gülmez D, Arikan-Akdagli S. The impact of the COVID-19 on the antifungal consumption and antifungal resistance in Candida species isolated from the blood cultures of critically ill patients in intensive care units. Med Mycol 2025 Jan 25;63(2):myaf002. doi: 10.1093/mmy/myaf002.

            https://pubmed.ncbi.nlm.nih.gov/39814570/

  • Karadogan E, Sertcelik A, Dizman GT, Uzar H, Hazirolan G, Cakir B, Metan G. A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosaJ Antimicrob Chemother 2025 Mar 3;80(3):788-796. doi: 10.1093/jac/dkae476.

           https://pubmed.ncbi.nlm.nih.gov/39811889/

  • Dogan CZ, Kara E, Pinar A, Demirkan K, Metan G. Therapeutic drug monitoring in patients treated with vancomycin: a single center, prospective, observational, real-world study. Eur J Clin Microbiol Infect Dis. 2025 Jun 13. doi: 10.1007/s10096-025-05182-w. 

           https://pubmed.ncbi.nlm.nih.gov/40512250/ 

  • Ocaklı Aİ, Özyar-Kurtçu ŞA, Uzun M, Kaşıkçı-Çavdar M, Telli-Dizman G, Metan G, Akova M, Sarıbaş Z, Şener B. Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Türkiye. Infect Dis Clin Microbiol. 2025 Jun 26;7(2):156-165. doi: 10.36519/idcm.2025.546.

           https://pubmed.ncbi.nlm.nih.gov/40657012/

  • Ballı Turhan FN, Bakır Ekinci P, Kurtaran M, Kara E, Telli Dizman G, Sönmezer MÇ, Hayran M, Demirkan K, Metan G. In reply to the letter to the editor regarding 'battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin'. Int J Antimicrob Agents. 2025 Jul 16;66(4):107576. doi: 10.1016/j.ijantimicag.2025.107576. 

            https://pubmed.ncbi.nlm.nih.gov/40675198/

  • Yumrukaya L, Hagens A, İnkaya AÇ, Metan G, Postma M, Yeğenoğlu S, Akova M. Do We Need Meropenem Treatment Beyond 7 Days in Febrile Neutropenic Patients: A Cost-Effectiveness Analysis. Antibiotics (Basel). 2025 Jun 27;14(7):653. doi: 10.3390/antibiotics14070653.

           https://pubmed.ncbi.nlm.nih.gov/40723956/

  • Aslan AT, Kara E, Köksal G, Bilir Y, Saraçoğlu KT, Eser F, Güner R, Alkan S, D'Avino A, Escudero-Sanchez R, Kutluca K, Kaya SY, Saltoğlu N, Loiacono L, Coladonato S, Del Giacomo P, Cascio A, Pallotto C, Francisci D, Öztürk B, Pınar A, Dağ O, Harris PNA, Paterson DL, Akova M. Comparison of piperacillin-tazobactam and vancomycin (TZP-VAN) with piperacillin-tazobactam and teicoplanin (TZP-TEI) for the risk of acute kidney injury (CONCOMITANT): A prospective observational, multinational, multi-centre cohort study. Int J Antimicrob Agents 2025 Mar;65(3):107446. doi: 10.1016/j.ijantimicag.2025.107446.

           https://pubmed.ncbi.nlm.nih.gov/39826571/

  • Righi E, Yahav D, Nasim A, Akova M, Barac A, Scudeller L, Nagavci B, Armellini M, Zanchi C, Shirin N, Tunali V, Paño-Pardo JR, Rodríguez-Baño J, Jamrozik E; ESCMID OPENING Project Group. Incorporating ethics into infectious disease clinical practice guidelines. Clin Microbiol Infect 2025 Jan 17:S1198-743X(25)00013-8. xdoi: 10.1016/j.cmi.2025.01.008.

           https://pubmed.ncbi.nlm.nih.gov/39827993/

  • Moreno-Mellado E, Aslan AT, Akova M, León E, Merchante N, Vinuesa D, Moral-Escudero E, Sadyrbaeva-Dolgova S, López-Cárdenas S, Cano-Yuste Á, Rinaldi M, Núñez-Núñez M, Giannella M, Sojo-Dorado J, Antolí-Royo AC, Chacón N, Merino-Bohórquez V, Portillo I, Rodríguez-Baño J, Docobo-Pérez F, Gutiérrez-Gutiérrez B; FOSFOMIC team. Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC projectClin Microbiol Infect 2025 Jan 18:S1198-743X(25)00012-6. doi: 10.1016/j.cmi.2025.01.007.

           https://pubmed.ncbi.nlm.nih.gov/39832652/